Research programme: cell based therapeutics - Propagenix

Drug Profile

Research programme: cell based therapeutics - Propagenix

Latest Information Update: 03 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Propagenix
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Burns; Respiratory tract disorders; Type 1 diabetes mellitus

Most Recent Events

  • 21 Jun 2017 Cell based therapeutics - Propagenix is available for licensing as of 21 Jun 2017.
  • 21 Jun 2017 Propagenix in-licenses Conditional Reprogramming technology from Georgetown University prior to June 2017
  • 21 Jun 2017 Propagenix receives SBIR grant from the National Institute of Diabetes and Digestive and Kidney Diseases for development of cell therapies in Type-1 diabetes mellitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top